Core Viewpoint - Zhonghui Biotech-B (02627) has achieved a significant milestone with the approval of China's first and only trivalent subunit influenza virus vaccine for the entire population, enhancing its product matrix in the subunit influenza vaccine sector [1][4]. Group 1: Product Development and Market Position - The company previously launched the first and only quadrivalent subunit influenza vaccine (Hui Er Kang Xin) for the entire population, establishing a comprehensive product matrix that meets diverse public health needs and market preferences [4]. - The successful approval of the trivalent vaccine is expected to drive the company's performance and value reassessment, as it aligns with the growing demand for influenza vaccination in China, where the vaccination rate is significantly lower than in the U.S. [5][6]. - The trivalent subunit vaccine is designed to have high antigen purity and fewer adverse reactions, making it particularly suitable for vulnerable populations such as children and the elderly [6]. Group 2: Financial Performance and Market Dynamics - Following the commercialization of the quadrivalent vaccine, the company has seen rapid revenue growth, with projected revenues increasing from 52.168 million yuan in 2023 to 260 million yuan in 2024, and a staggering 918.91% year-on-year growth in the first half of 2025 [7]. - The quadrivalent vaccine has achieved a 100% approval rate for product batch issuance and has expanded its sales network to over 1,100 disease control centers across 30 provinces in China [7]. - The company has also made progress in market access, with the quadrivalent vaccine passing preliminary review for inclusion in the 2025 National Commercial Health Insurance innovative drug list, which is expected to alleviate market promotion pressures [7]. Group 3: Future Growth and R&D Pipeline - The company is actively expanding its product offerings, including a clinical trial for an adjuvanted vaccine targeting individuals aged 65 and older, and research for a vaccine specifically for pregnant women, which could fill a current gap in immunization for infants aged 0-6 months [8]. - The company has a robust R&D pipeline, with multiple promising products under development, including a freeze-dried rabies vaccine and other vaccines targeting pneumonia and shingles, ensuring long-term sustainable growth [9][10]. - The company is also expanding its international market presence, with plans to enter markets in Canada, Singapore, Mexico, and Hong Kong by 2026, leveraging the seasonal differences in influenza activity across regions [11]. Group 4: Market Outlook and Investment Potential - Analysts predict that the company will achieve profitability by 2027, with projected revenues of 798 million yuan and 1.24 billion yuan in 2026 and 2027, respectively, indicating a clear growth trajectory [11]. - The successful approval of the trivalent influenza vaccine is expected to provide immediate revenue growth and enhance the company's competitive advantage in the high-potential subunit vaccine sector [11].

Core Viewpoint - Shenzhou Cell (688520.SH) is expected to report a significant net loss for the year 2025, with projected losses ranging from -5.8 billion to -5.2 billion yuan, primarily due to declining sales and increased commercialization costs [1] Financial Performance - The net profit attributable to the parent company is forecasted to be between -5.8 billion and -5.2 billion yuan for 2025 [1] - The net profit after deducting non-recurring gains and losses is expected to be between -5.63 billion and -5.03 billion yuan [1] - Research and development expenditures for 2025 are projected to be between 830 million and 870 million yuan [1] Reasons for Performance Change - The decline in sales revenue is attributed to the ongoing tightening of healthcare cost control policies and significant price reductions of the core product, Anjia [1] - Increased upfront commercialization investments, including academic promotion and sales team formation, have led to a noticeable rise in sales expenses [1] - The company continues to pursue a multi-product pipeline strategy, with several projects entering critical confirmatory clinical trial phases, maintaining high levels of R&D investment, which has impacted current profitability [1]

Core Viewpoint - Anxu Bio (688075.SH) expects a significant decline in net profit for the year 2025, with projections indicating a decrease of 55.80% to 63.08% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 71 million to 85 million yuan for 2025 [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 13 million and 15.6 million yuan, reflecting a year-on-year decrease of 58.84% to 65.70% [1] Business Development - The company's main business remains stable, and it continues to invest strategically in new technology platforms while maintaining the advancement of existing ones [1] - Efforts to expand in domestic and international markets, as well as obtaining registration certificates, have led to increased expenses [1] External Factors - The increase in tariffs imposed by the U.S. government has resulted in a reduction of orders in certain regional markets, contributing to higher operating costs for the company [1] - Additional factors affecting profit include exchange rate fluctuations leading to foreign exchange losses, reduced interest income, and depreciation and amortization of assets [1]

每经AI快讯，1月30日，科兴制药(688136.SH)公告称，预计2025年归属于上市公司股东的净利润为1.35 亿元至1.75亿元，同比增长328.83%-455.89%。业绩变动主要原因系公司积极开拓海外市场，实现海外 收入强劲增长，推动营业收入持续增长，带动净利润大幅上升。 （文章来源：每日经济新闻） ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 華潤博雅生物截至2025年12月31日止年度的 業績預告 於 2026 年 1 月 30 日， 華 潤 博雅 生 物 公 佈其 截 至 2025 年 12 月31 日 止年 度 的 業績 預 告。 華潤博雅生物製藥集團股份有限公司（「華潤博雅生物」）為一家於中華人民共和國 註 冊 成 立 的 公 司 。 華 潤 博 雅 生 物 的 股 份 於 深 圳 證 券 交 易 所 上 市 。 截 至 本 公 告 日 期，華潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）間接持 有華潤博雅生物總股本約30.48 %及總股本約41.79 %表決權，因此華潤博雅生物為 本公司的附屬公司。 於 2026 年 1 月 30 日 ， 華 潤 博 雅 生 物 公 佈 其 截 至 2025 ...

Core Viewpoint - Zhonghui Biotech-B (02627) has achieved a significant milestone with the approval of the first and only trivalent subunit influenza vaccine for the entire population in China, enhancing its product matrix in the subunit influenza vaccine sector [1][4]. Group 1: Product Development and Market Position - The company’s quadrivalent subunit influenza vaccine (Hui Er Kang Xin®) was the first to achieve full population coverage in China, establishing a strong foundation for the newly approved trivalent vaccine [4]. - The successful approval of the trivalent vaccine allows the company to better meet diverse public health needs and market preferences, potentially driving sustained performance and value reassessment [4][8]. - The global influenza activity has been increasing, with a significant gap in vaccination rates in China compared to international levels, indicating a long-term structural growth opportunity for the company [5]. Group 2: Commercialization and Financial Performance - The quadrivalent vaccine has demonstrated strong commercial viability, with revenue projected to grow from 52.168 million yuan in 2023 to 260 million yuan in 2024, and a staggering 918.91% year-on-year growth in the first half of 2025 [7]. - The vaccine has maintained a 100% approval rate for product batch issuance since its launch, expanding its sales network across over 1,100 disease control centers in 30 provinces [7]. - The company has made progress in market access, with the quadrivalent vaccine passing preliminary review for inclusion in the 2025 National Commercial Health Insurance innovative drug list, which may alleviate market promotion pressures [7]. Group 3: Future Growth and R&D Pipeline - The company is actively expanding its product offerings, including a clinical trial for an adjuvanted vaccine targeting individuals aged 65 and older, and research for a vaccine specifically for pregnant women [8][10]. - The company has a robust pipeline with multiple promising products, including a freeze-dried rabies vaccine currently in phase III clinical trials, which is expected to become a significant growth driver alongside the influenza vaccines [10]. - The company is also pursuing international markets, with plans to expand into Canada, Singapore, Mexico, and Hong Kong by 2026, enhancing its global competitiveness [11]. Group 4: Market Outlook and Analyst Ratings - Analysts predict that the company will achieve profitability by 2027, with projected revenues of 798 million yuan and 1.24 billion yuan for 2026 and 2027, respectively, indicating a clear growth trajectory [11]. - The successful approval of the trivalent influenza vaccine is expected to provide immediate revenue growth and strengthen the company's competitive advantage in the high-potential subunit vaccine sector [11].

Group 1 - Tyligand Bioscience has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [3] - The company, founded in 2017, focuses on discovering and developing innovative cancer therapies and currently holds 97 patents and patent applications, including 25 related to its core product TSN1611 [4] - Tyligand Bioscience has not yet received any market approval for its candidate drugs and has not generated any revenue from product sales [4] Group 2 - As of December 31, 2023, the company reported revenues of 7.856 million RMB, 1.506 million RMB for the nine months ending September 30, 2024, and 11.358 million RMB for the first nine months of 2025 [7] - The company incurred losses of 70.461 million RMB, 28.354 million RMB, and 123.406 million RMB for the respective periods [7] - Revenue sources include providing research and development services and intellectual property licensing [7]

每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 每经AI快讯，科兴制药1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 为1.35亿元~1.75亿元，与上年同期相比，将增加约1.04亿元至1.44亿元，同比增加328.83%~455.89%。 业绩变动主要原因是，2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收 入持续增长，归属于母公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提 升。报告期内非经常性损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子 公司所致。 （记者 曾健辉） ...

Core Viewpoint - Bailitianheng (688506.SH) is expected to report a net loss of approximately 1.1 billion yuan for the fiscal year 2025, a significant shift from a profit of 3.708 billion yuan in the previous year, indicating a year-on-year turnaround to loss [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately -1.1 billion yuan for 2025, compared to a profit of 3.708 billion yuan in the same period last year, reflecting a year-on-year decline [1] - The decrease in revenue during the reporting period is primarily attributed to the recognition of intellectual property income from a previous upfront payment from BMS, which was greater than the milestone income recognized in the current reporting period [1] Research and Development - Bailitianheng has significantly increased its R&D investment, leading to a substantial year-on-year growth in R&D expenditures [1] - As of the end of the reporting period, the company has 17 innovative drugs in clinical trial stages, with 6 of these drugs undergoing global clinical trials [1] - The company is conducting over 100 innovative drug clinical trials globally [1] Product Development - The core product, iza-bren (EGFR×HER3 dual antibody ADC), has had its New Drug Application (NDA) accepted by the National Medical Products Administration (NMPA) and included in the priority review process for two indications: treatment of locally advanced or metastatic nasopharyngeal carcinoma and treatment of recurrent or metastatic esophageal squamous cell carcinoma [1]

南财智讯1月30日电，荣昌生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润约为 71,600万元，实现扭亏为盈；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润约为 7,850万元，实现扭亏为盈。本期业绩变化的主要原因：（一）主营业务的影响：本年度，公司核心产 品泰它西普、维迪西妥单抗国内销售收入实现快速增长，成为业绩核心增长引擎；同时，公司成功达成 重磅合作，授予VorBiopharmaInc泰它西普除大中华区以外全球范围内的独家开发与商业化权利，技术 授权收入大幅增加，部分海外研发投入由授权方承担。此外，公司通过优化管理、迭代生产工艺等举 措，降低了产品单位生产成本，提升了产品毛利率，另外，销售费用率明显下降。综合多方面积极因 素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。（二）非经常性损益的影响：本年 度自上述授权交易取得的认股权证公允价值变动属于非经常性损益，在扣除非经常性损益的影响后，预 计公司2025年度归属于上市公司股东的扣除非经常性损益后的净利润实现扭亏为盈。 ...